The Technical Analyst
Minerva Neurosciences Inc [NERV]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Minerva Neurosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.08% $0.381
Last updated: 16 May 2022 @ 10:56 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 16.28 mill |
| EPS: | -1.170 |
| P/E: | 0.000 |
| Earnings Date: | Aug 01, 2022 |
| SharesOutstanding: | 42.72 mill |
| Avg Daily Volume: | 0.0887 mill |
| RATING 2022-05-13 |
|---|
| B- |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| True Range Average |
|---|
|
+/- $0.0710 ( +/- 18.44%) Range: 0.314 - 0.456 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-16 | Luthringer Remy | Buy | 505 000 | Employee Stock Option (right to buy) |
| 2022-02-16 | Race Geoff | Buy | 200 000 | Employee Stock Option (right to buy) |
| 2022-02-16 | Ahlholm Frederick W | Buy | 180 000 | Employee Stock Option (right to buy) |
| 2021-12-01 | Kupfer David | Sell | 55 635 | Common Stock |
| 2021-06-11 | Doyle William F | Buy | 40 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 79.37 |
| Last 100 transactions |
| Buy: 4 324 750 | Sell: 923 809 |
Forecast:
12:29 - $0.387
Live Trading Signals (every 1 min)
Forecast
1: 10:59 - $0.384
Forecast 2: 11:49 - $0.391
Forecast 3: 12:29 - $0.387
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.381 (0.08% ) |
| Volume | 0.0257 mill |
| Avg. Vol. | 0.0887 mill |
| % of Avg. Vol | 28.99 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
NERV
Latest Press Releases
2022-05-04 08:30:00 - Press Release
Minerva Neurosciences Reports First Quarter 2022 Financial Results And Business Updates
Company expects to submit an nda for roluperidone, subject to fda guidance, in the third quarter of 2022 company expects to submit an nda for roluperidone, subject to fda guidance, in the third quarter of 2022
2022-04-07 08:30:00 - Press Release
Minerva Neurosciences Provides Update From Type C Meeting With Fda And Next Steps In Preparation For Submission Of A New Drug Application (nda) For Roluperidone For The Treatment Of Negative Symptoms In Schizophrenia
Company to host webcast wednesday, april 13, 2022 at 11am et company to host webcast wednesday, april 13, 2022 at 11am et
2022-03-01 07:30:00 - Press Release
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results And Business Updates
Waltham, mass., march 01, 2022 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today reported key business updates and financial results for the fourth quarter ended december 31, 2021. the company is not hosting a call this quarter as it prepares for a meeting with the fda and anticipates providing an update after the meeting, as appropriate.
2022-02-28 08:30:00 - Press Release
Minerva Neurosciences Announces Publication Of Roluperidone Phase 3 Study Results In Schizophrenia Bulletin
Trial results confirm the potential of roluperidone to treat negative symptoms and improve everyday functioning in patients with schizophrenia trial results confirm the potential of roluperidone to treat negative symptoms and improve everyday functioning in patients with schizophrenia
2021-11-08 07:30:00 - Press Release
Minerva Neurosciences Reports Third Quarter 2021 Financial Results And Business Updates
Company to host conference call today at 8:30 a.m. et
Latest News
2022-04-07 13:01:05 - Benzinga
Minerva Outlines Next Steps For US Application For Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. The agency cited concerns related to the applicability of the results of the Phase 2b.
2022-03-01 10:44:34 - Zacks Investment Research
Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-08 14:11:04 - Seeking Alpha
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript
2021-11-08 10:00:59 - Zacks Investment Research
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-01 08:30:00 - GlobeNewsWire
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
2021-10-11 08:30:00 - GlobeNewsWire
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA
2021-09-30 10:32:12 - Benzinga
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Related Link: Minerva's Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning
2021-09-30 08:30:00 - GlobeNewsWire
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration
2021-09-27 10:03:21 - Zacks Investment Research
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
2021-08-02 12:19:07 - Seeking Alpha
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript